Helicobacter Pylori Eradication and Upper Gastrointestinal Endoscopic Management
This research community focuses on the clinical management of Helicobacter pylori infection and the endoscopic treatment of upper gastrointestinal disorders, including acid-related diseases and early-stage gastric neoplasia.
The work centers on optimizing antibiotic regimens, specifically bismuth-containing quadruple therapies and potassium-competitive acid blockers, to achieve high eradication rates. It integrates these pharmacological approaches with advanced endoscopic techniques, such as endoscopic submucosal dissection for early gastric cancer and endoscopic myotomy for motility disorders. The literature extensively evaluates the efficacy and safety of these interventions through randomized controlled trials and systematic meta-analyses, while also addressing the management of complications like gastrointestinal bleeding and the long-term monitoring of conditions such as Barrett’s esophagus and gastric cancer.
The largest share of the community's output is found in barium research, accounting for 4.7% of all barium-related papers, and bismuth research, accounting for 2.6%. Barium also contributes the highest absolute number of papers within this group, with 4,055 entries.
The community comprises 29,045 papers, published predominantly in the World Journal of Gastroenterology, Gastroenterology, and Gastrointestinal Endoscopy.
Recent work continues to refine Helicobacter pylori management, with new consensus guidelines from Taipei and Japan, and randomized trials evaluating vonoprazan-based dual therapies. Concurrently, research addresses the diagnosis and management of gastroparesis, autoimmune gastritis, and functional esophageal disorders, alongside quality improvement initiatives for upper gastrointestinal endoscopy.